

# Cameron J Turtle

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4656410/cameron-j-turtle-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

7,696

citations

34

h-index

75

g-index

75

ext. papers

10,228

ext. citations

5.9

avg, IF

6.14

L-index

#	Paper	IF	Citations
69	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2123-38	15.9	1143
68	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 625-638	4.7	874
67	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1404-1419	24.4	649
66	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 355ra116	17.5	613
65	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. <i>Blood</i> , <b>2017</b> , 130, 2295-2306	2.2	522
64	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , <b>2016</b> , 127, 2406-10	2.2	436
63	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3010-3020	2.2	396
62	Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 1233-1244	35.1	395
61	Overlap and effective size of the human CD8+ T cell receptor repertoire. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 47ra64	17.5	286
60	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , <b>2018</b> , 131, 121-130	2.2	225
59	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , <b>2019</b> , 133, 1652-1663	2.2	158
58	A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. <i>Immunity</i> , <b>2009</b> , 31, 834-44	32.3	140
57	Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. <i>Cancer Discovery</i> , <b>2018</b> , 8, 750-763	24.4	136
56	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , <b>2019</b> , 133, 1876-1887	2.2	126
55	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , <b>2020</b> , 135, 1650-1660	2.2	115
54	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. <i>CNS Drugs</i> , <b>2018</b> , 32, 1091-1101	6.7	110
53	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 26-33	4.7	100

52	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , <b>2019</b> , 134, 636-640	2.2	89
51	Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. <i>Drugs</i> , <b>2017</b> , 77, 237-245	12.1	84
50	Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 705-16	4.7	75
49	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. <i>Current Research in Translational Medicine</i> , <b>2018</b> , 66, 50-52	3.7	67
48	Artificial antigen-presenting cells for use in adoptive immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 374-81	2.2	66
47	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events <b>2020</b> , 8,		66
46	Engineered T cells for anti-cancer therapy. <i>Current Opinion in Immunology</i> , <b>2012</b> , 24, 633-9	7.8	62
45	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1011-1011	2.2	62
44	Toxicities of CD19 CAR-T cell immunotherapy. <i>American Journal of Hematology</i> , <b>2019</b> , 94, S42-S49	7.1	57
43	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 242-251	4.7	46
42	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 34-43	4.7	40
41	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E209-E213	7.1	39
40	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , <b>2021</b> , 137, 323-335	2.2	39
39	Cytokines in CAR T Cell-Associated Neurotoxicity. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 577027	8.4	37
38	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , <b>2019</b> , 3, 3062-3069	7.8	37
37	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , <b>2015</b> , 126, 184-184	2.2	36
36	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1706-1715	4.4	34
35	Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. <i>Current Opinion in Immunology</i> , <b>2011</b> , 23, 299-305	7.8	31

34	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. <i>Blood</i> , <b>2020</b> , 136, 137-139	2.2	29
33	Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 780-784	4.4	29
32	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3773-3773	2.2	29
31	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , <b>2019</b> , 3, 3590-3601	7.8	27
30	Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. <i>Journal of Immunology</i> , <b>2019</b> , 202, 476-483	5.3	27
29	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 2270-2280	19.7	20
28	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , <b>2020</b> , 58, 58-64	4	19
27	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 653-664	5.4	18
26	CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncotarget</i> , <b>2016</b> , 5, e1168555	7.2	14
25	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , <b>2018</b> , 132, 94-94	2.2	10
24	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 56-56	2.2	10
23	Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. <i>Blood</i> , <b>2021</b> ,	2.2	9
22	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , <b>2020</b> , 4, 4869-4872	7.8	8
21	CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. <i>BioDrugs</i> , <b>2021</b> , 35, 281-302	7.9	7
20	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , <b>2020</b> , 4, 3239-3245	7.8	6
19	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. <i>Blood Advances</i> , <b>2021</b> ,	7.8	5
18	Neurotoxicities After CAR T-Cell Immunotherapy <b>2020</b> , 83-105		5
17	Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model. <i>Blood</i> , <b>2019</b> , 134, 2866-2866	2.2	4

16	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	4
15	Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
14	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy <b>2021</b> ,		3
13	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 38-39	2.2	2
12	Generation of CD8+ Cytotoxic T Cell Clones Recognizing BMI1-Derived Peptides. <i>Blood</i> , <b>2008</b> , 112, 2909-2909		2
11	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , <b>2021</b> , 138, 422-422	2.2	2
10	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , <b>2021</b> , 17, 3549-3560	3.6	2
9	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 1-2	2.2	1
8	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Blood</i> , <b>2019</b> , 134, 4453-4453	2.2	1
7	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. <i>Blood</i> , <b>2021</b> , 138, 3872-3872	2.2	1
6	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study <b>2021</b> , 9,		1
5	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2021</b> , 27, 98-106	2.2	0
4	Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. <i>Journal of Immunological Methods</i> , <b>2021</b> , 492, 112955	2.5	0
3	Toxicities of CD19-targeted CAR-T cell therapy. <i>Pathology</i> , <b>2018</b> , 50, S39-S40	1.6	
2	Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy. <i>Blood</i> , <b>2021</b> , 138, 2776-2776	2.2	
1	Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8+ T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , <b>2011</b> , 118, 2978-2978	2.2	